Podcast

What Patients With Blood Cancers Need to Know About COVID-19, Booster Shots and More

Author(s):

An expert from the Leukemia & Lymphoma Society breaks down the effectiveness of the COVID-19 vaccine in patients with blood cancers on this episode of the “Cancer Horizons” podcast.

With recent research demonstrating that antibodies were not detected in some patients with B-cell blood cancers after receiving two doses of the COVID-19 vaccine, many people have questions. Will a third dose help these patients? Should they bother with the vaccine? How do their current cancer treatments impact the vaccine’s effectiveness?

Dr. Larry Saltzman, the executive research director at the Leukemia & Lymphoma Society, answered these questions and more in this episode of the “Cancer Horizons” podcast.

“So there's two swings of the pendulum, those who will respond in a global, very good way – not to worry, essentially, and those (who) will not respond due to the treatments that they're on,” Saltzman said.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Related Content